Skip to main content

DxS, ParAllele BioScience, Translational Genomics Research Institute

Premium

DxS has launched a single-tube genotyping assay in its Scorpions fluorescent-detection technology line for the drug-metabolism gene UGT 1A1*28, the company said last week. The test can deliver results "within 30 minutes" and can be used with both real-time or end-point analysis, the company said.


ParAllele BioScience now offers 20,000 non-synonymous SNPs — up from 10,000 — as part of its human genotyping service, the company said last week. The latest SNP selection was obtained by genotyping "approximately 300" individuals from three ethnic populations, resulting in "more than 8 million" genotypes, the company said.


The Translational Genomics Research Institute has launched its MammaPrint gene-expression profile microarray diagnostic for breast cancer in the United States, the company said in a statement this week. The test "distinguishes between lymph node-negative breast cancer patients who would benefit from additional therapy from those who would not," the company said.

Filed under

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.